FDA CDER Impact Story: Real-world equivalence, just like clinical trial data, confirms that generic drugs are therapeutically equivalent to brand-name drugs
Increasing generic drug competition can help patients to have access to more affordable therapies, which is a critical part of the CDER mission. CDER investigations identify drug and regulatory characteristics that appear to facilitate generic drug development.
This is an automated message delivery system. Replying to this message will not reach DDI staff. If you have comments or questions, please contact us at: 1-888-INFO- FDA (1-888-463-6332) or 301-796-3400 from 8:00 am - 4:30 pm ET Monday - Friday. You can also email us at: druginfo@fda.hhs.gov.
Stay Connected with U.S. Food and Drug Administration: